AMOGEN Pharma

    ​

    Recombinant peptide and protein biosimilars, built for global supply.

    Our innovator-aligned microbial platforms deliver the purity, scale, and regulatory confidence global pharmaceutical partners need.

    Amogen Pharma Plant 1 Hyderabad — India largest recombinant peptide API facility
    Partner With UsView Pipeline >

    WHY AMOGEN?

    Precision manufacturing, scaled for global biosimilar supply.

    Amogen combines microbial expression expertise, fermentation capacity, and process discipline to advance recombinant biosimilars from development to dependable long-term supply.

    Amogen Pharma Plant 1 facility aerial view — Hyderabad recombinant biosimilar manufacturing
    75,000L

    Total Fermentation Capacity

    S. cerevisiae and multi-microbial suites facility
    75+

    Scientific & Manufacturing Experts

    84% in R&D and manufacturing functions, averaging 15 years of peptide expertise.

    980+Kgs

    Semaglutide API Capacity

    Annual recombinant semaglutide manufacturing capacity

    HOW WE BUILD BIOSIMILARS

    Proprietary platforms, built to advance high-barrier recombinant biosimilars

    Amogen scientist working in recombinant biosimilar research laboratory

    Amogen's science is built on innovator-aligned microbial expression and manufacturing systems designed to deliver the purity, scalability, and process consistency your regulatory submissions demand.

    Proprietary Platforms

    Proprietary microbial expression systems, led by YESTIDE™, our yeast-based platform engineered to support recombinant peptide and protein biosimilars across GLP-1, insulin, and immunology.

    Manufacturing Systems

    Advanced fermentation and downstream systems, led by CONTINEX™, our continuous manufacturing platform designed to deliver process consistency, scalable output, and dependable long-term supply.

    From Platform to Pipeline

    Platform science delivered as active biosimilar programs — with confirmed FTO in key global markets and structured pathways for licensing and supply.

    A focused pipeline of high-value recombinant biosimilars.

    Our growing portfolio of recombinant biosimilar programs across GLP-1, insulin, and immunology spans various stages of development with confirmed FTO in key global markets and structured pathways for licensing and supply.

    Program
    DevelopmentAnalytical CMCPre-Clinical
    Semaglutide Biosimilar
    Liraglutide Biosimilar
    INSULIN ANALOGS
    Insulin Degludec Biosimilar
    Insulin Aspart Biosimilar
    IMMUNOLOGY
    Certolizumab Biosimilar
    Anakinra Biosimilar
    View Full Pipeline →

    FROM LAB TO COMMERCIAL SUPPLY

    One integrated facility for your
    recombinant peptide and protein programs.

    Whether advancing a peptide through early development or scaling toward commercial supply, Amogen provides the full suite of recombinant manufacturing capabilities under one roof.

    Explore our CDMO services →
    API MANUFACTURING

    Manufacturing capabilities

    Pre-Seed Bioreactor (100L) x2

    Pre-Seed Bioreactor (100L) x2

    Seed Bioreactor (1000L) x4

    Seed Bioreactor (1000L) x4

    Production Bioreactor (10000L) x5

    Production Bioreactor (10000L) x5

    Continuous Centrifuge

    Continuous Centrifuge

    Downstream Purification

    Downstream Purification

    Preparative Chromatography

    Preparative Chromatography

    RESEARCH & DEVELOPMENT

    R&D Capabilities

    Sequence & Construct Engineering

    Sequence & Construct Engineering

    Multi-Host Expression Platforms

    Multi-Host Expression Platforms

    Strain / Clone Development

    Strain / Clone Development

    Cell Banking & Stability Systems

    Cell Banking & Stability Systems

    Media & Seed Train Optimization

    Media & Seed Train Optimization

    Scalable Fermentation Development

    Scalable Fermentation Development

    ANALYTICAL

    Analytical Capabilities

    UHPLC

    UHPLC

    HPLC-UV/PDA

    HPLC-UV/PDA

    LC–MS

    LC–MS

    HRMS

    HRMS

    SEC-HPLC

    SEC-HPLC

    qPCR

    qPCR

    Partner with us →

    We're looking for pharma companies that think long term.

    Meet the Team

    The team behind the platform.

    75+ years of combined experience in science, manufacturing and biopharmaceutical strategy.

    Our leadership

    P.V.S.N. Raju

    P.V.S.N. Raju

    Chairman & MD

    Seasoned Entrepreneur & Engineering Excellence

    P. Akhilesh Raju

    P. Akhilesh Raju

    Chief Executive Officer

    MBA · Anglia Ruskin

    Dr. T Devi Kalyan

    Dr. T Devi Kalyan

    Chief Operating Officer

    PhD · DRDO

    Biological EDr. Reddy's
    Harmeet Lamba

    Harmeet Lamba

    Advisor

    MBA · Wharton BS

    RanbaxyDr. Reddy's
    Dr. Manpreet Singh

    Dr. Manpreet Singh

    Vice President, BD

    PhD · NIPER

    Dr. Reddy'sAurisco
    Who we are →

    News and insights

    See all news →
    1 of 3

    AVAILABLE FOR PARTNERSHIP

    Recombinant APIs and drug products, ready for global licensing and supply.

    A growing portfolio of recombinant peptide and protein drugs — from GLP-1 agonists and insulin analogues to immunology biosimilars — manufactured at commercial scale and backed by full regulatory documentation.

    View Product Portfolio